299 related articles for article (PubMed ID: 14563573)
1. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
[TBL] [Abstract][Full Text] [Related]
3. The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Cohen M; Maritz F; Gensini GF; Danchin N; Timerman A; Huber K; Gurfinkel EP; White H; Fox KA; Vittori L; Le-Louer V; Bigonzi F
J Thromb Thrombolysis; 2000 Dec; 10(3):241-6. PubMed ID: 11122544
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Santopinto J; Hecquet C; Vittori L;
Circulation; 2003 Oct; 108(16 Suppl 1):III14-21. PubMed ID: 14605015
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
[TBL] [Abstract][Full Text] [Related]
7. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
[TBL] [Abstract][Full Text] [Related]
10. Optimizing outcomes in ST-segment elevation myocardial infarction.
Herrmann HC
J Am Coll Cardiol; 2003 Oct; 42(8):1357-9. PubMed ID: 14563574
[No Abstract] [Full Text] [Related]
11. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
[TBL] [Abstract][Full Text] [Related]
12. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
Bugiardini R; Dorobantu M; Vasiljevic Z; Kedev S; Knežević B; Miličić D; Calmac L; Trninic D; Daullxhiu I; Cenko E; Ricci B; Puddu PE; Manfrini O; Koller A; Badimon L;
Atherosclerosis; 2015 Jul; 241(1):151-6. PubMed ID: 25988359
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
de Lemos JA; Blazing MA; Wiviott SD; Brady WE; White HD; Fox KA; Palmisano J; Ramsey KE; Bilheimer DW; Lewis EF; Pfeffer M; Califf RM; Braunwald E;
Eur Heart J; 2004 Oct; 25(19):1688-94. PubMed ID: 15451146
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
Lavi S; Cantor WJ; Casanova A; Tan MK; Yan AT; Džavík V; Fitchett D; Cohen EA; Borgundvaag B; Heffernan M; Ducas J; Goodman SG
Am Heart J; 2012 Feb; 163(2):176-81.e2. PubMed ID: 22305834
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
17. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
[TBL] [Abstract][Full Text] [Related]
19. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
20. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ;
JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
